Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CardioFlow Releases One-year Clinical Outcome of VitaFlow®

[2018-05-17] 

Suzhou, China – From March 22 to March 25, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), attended CIT 2018 and released the one-year clinical outcome of VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®").
 
Transcatheter aortic valve replacement ("TAVR") is an innovative solution for aortic valve stenosis emerging in the 21 century. In the past 15 years, TAVR experienced fast development which has revolutionized the cardiovascular industry. The CIT 2018 gathered several domestic and overseas experts to have in-depth discussion on the current situation and future development of the TAVR technology. On March 24, in "PCR at CIT – Part One: TAVI Treating Aortic Stenosis With Complex Anatomy", Academician Junbo Ge of Zhongshan Hospital of Fudan University for the first time released the one-year follow-up result of VitaFlow® which demonstrated that VitaFlow® is safe and effective in treating severe calcified aortic stenosis.
 
The clinical study of VitaFlow® is a prospective, multi-center, single-arm trial, enrolling 110 aged patients suffering from severe calcified aortic stenosis who are either high-risk or can’t undergo open surgery, of which 42 have bicuspid aortic stenosis. Patients are followed up for 30 days, six months, one year, and two to five years after TAVR treatment. The One-year follow-up result shows, the occurrence of all-cause mortality is as low as 2.7%, and there is no major stroke. All of the patients reported good hemodynamic function, no moderate or severe PVL, and significant improvement in NYHA class (97% NYHA≤Ⅱ). The treatment outcomes of patients with BAV stenosis are similar with those who with tricuspid valve stenosis. The one-year clinical data of VitaFlow® is competitive compared to similar products.
 
VitaFlow® is consisted of transcatheter aortic valve, delivery system, balloon catheter and introducer set. Academician Junbo Ge introduced the design rationale of VitaFlow® series products and highly recognized their safe and effective clinical outcome as well as easy operation. VitaFlow® adopts innovative design with inner and outer skirts, which effectively reduce the occurrence of paravalvular leak. In addition, the low density cells design provides better alignment during deployment and large cell design leaves space for interventional treatment of coronary artery. Delivery system with motorized handle enables the physician to deploy the valve while controlling the guide wire, which improves the overall efficiency.
 
China has a higher percentage of BAV stenosis patients compared with Western countries, and so it has been the focus of the industry to figure out the safe and effective treatment of BAV stenosis. Academician Ge also introduced the subset analysis outcome of the clinical trial in his presentation, and concluded that there is no major difference in the clinical outcome of using VitaFlow® to treat patients with BAV stenosis and those who with tricuspid valve stenosis. After his presentation, experts in attendance had hot discussion on this clinical outcome and spoke highly of the excellent performance of VitaFlow® in treating BAV stenosis. Currently, VitaFlow® was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval, and is expected to gain CFDA approval in 2018, to benefit domestic patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC
[Next]:MicroPort® CardioFlow Attends Fourth China Valve (Hangzhou) Meeting